Preoperative Treatment With Cetuximab and/or IMC-A12

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by M.D. Anderson Cancer Center
Sponsor:
Collaborators:
ImClone LLC
Eli Lilly and Company
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00957853
First received: August 12, 2009
Last updated: March 3, 2014
Last verified: March 2014
  Purpose

The goal of this clinical research study is to give cetuximab and/or IMC-A12 before surgery for squamous cell carcinoma of the head and neck, in order to learn if these study drugs may cause changes in biomarkers. Biomarkers are chemical "markers" in the blood and/or tissue that may be related to a reaction to study treatment.

The safety of the study treatments will also be studied.


Condition Intervention Phase
Head and Neck Squamous Cell Carcinoma
Drug: Cetuximab
Drug: IMC-A12
Procedure: Surgical tumor resection
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Exploratory Study to Assess the Modulation of Biomarkers in Patients With Squamous Cell Carcinomas of the Head and Neck Randomized to Receive Preoperative Treatment With Cetuximab and/or IMC-A12, an Anti-insulin-like Growth Factor-1 Receptor Monoclonal Antibody

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Modulation of phospho-Akt (difference in IHC score between the surgical specimen and the baseline biopsy) [ Time Frame: Biopsy at baseline and surgery (surgery should be within 10 days of last treatment). ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: October 2011
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1: Cetuximab
Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes
Drug: Cetuximab
First dose of 400 mg/m^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m^2 on week 2 and 3 (if applicable) given over 1 hour.
Other Names:
  • C225
  • Erbitux
  • IMC-C225
Procedure: Surgical tumor resection
Surgical tumor resection on Day 10.
Experimental: Group 2: IMC-A12
IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3.
Drug: IMC-A12
6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
Procedure: Surgical tumor resection
Surgical tumor resection on Day 10.
Experimental: Group 3: Cetuximab + IMC-A12

Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes.

IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3.

Drug: Cetuximab
First dose of 400 mg/m^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m^2 on week 2 and 3 (if applicable) given over 1 hour.
Other Names:
  • C225
  • Erbitux
  • IMC-C225
Drug: IMC-A12
6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
Procedure: Surgical tumor resection
Surgical tumor resection on Day 10.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically-confirmed diagnosis of squamous cell carcinoma of the head and neck (excluding carcinomas of the nasopharynx types II and III according to the World Health Organization criteria), for whom surgical resection of the tumor is planned as part of the treatment. Patients with skin squamous cell carcinomas of the head and neck region will also be included in this study.
  2. There is availability of a baseline, paraffin-embedded, tumor specimen for biomarker evaluation. No anti-neoplastic treatment is allowed between the time from obtaining the baseline tumor specimen and randomization. If a baseline tumor specimen is not available, a biopsy of the tumor will be performed prior to randomization.
  3. Prior treatment with biological agents targeted to the epidermal growth factor receptor is allowed, provided the time from last exposure to this treatment was >/= 6 months.
  4. The patient has a fasting serum glucose < 130 mg/dL and HbA1C < 7.0%. Patients with a history of diabetes mellitus are allowed to participate, provided that they are on a stable dietary or therapeutic regimen for this condition.
  5. The patient has adequate renal function, defined by serum creatinine </= 1.5 * the institutional upper limit of normal (ULN), or creatinine clearance >/=60 mL/min for patients with creatinine levels above the ULN.
  6. Because the teratogenicity of cetuximab and IMC-A12 is not known, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  7. The patient is age >/= 18 years.
  8. The patient or the patient's legally authorized representative has the ability to understand and the willingness to sign a written informed consent document.
  9. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

Exclusion Criteria:

  1. Patients receiving any other agent (investigational or not) with potential anti-neoplastic activity within 3 weeks prior to obtaining the baseline tumor specimen for biomarker evaluation.
  2. Patients receiving concomitant radiation.
  3. Prior treatment with an agent targeted at the insulin-like growth factor-1 receptor.
  4. History of allergic reactions attributed to compounds of chemical and biological composition similar to those of cetuximab or IMC-A12.
  5. Pregnant patients, or patients who are breast feeding (patients who have a positive pregnancy test within the first 30 days before the first dose of treatment are excluded).
  6. Patients with uncontrolled illnesses which, in the opinion of the investigator, could be aggravated by the administration of the study drug(s).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00957853

Contacts
Contact: William N. William Jr., MD 713-792-6363

Locations
United States, Texas
UT MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Principal Investigator: William N. William Jr., MD         
Sponsors and Collaborators
M.D. Anderson Cancer Center
ImClone LLC
Eli Lilly and Company
Investigators
Study Chair: William N. William Jr., MD UT MD Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00957853     History of Changes
Other Study ID Numbers: 2008-0342, NCI-2011-03039
Study First Received: August 12, 2009
Last Updated: March 3, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:
Head and Neck Cancer
Squamous cell carcinoma of the head and neck
HNSCC
Cetuximab
IMC-A12
Tumor
Biomarkers
Phospho-AKT
Surgical resection

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Antibodies, Monoclonal
Cetuximab
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 31, 2014